Envío gratis siempre a todo México.
Haz clic para hacer zoom
Not Available
Naresh Babu
Bioinformatics of Non Small Cell Lung Cancer and the Ras Proto-Oncogene
Cargando comentarios…
Comparte
$1,084
$976
Comentarios
Cargando el resumen…
Cargando comentarios…
product
2949728Bioinformatics of Non Small Cell Lung Cancer and the Ras Proto-Oncogenehttps://www.gandhi.com.mx/bioinformatics-of-non-small-cell-lung-cancer-and-the-ras-proto-oncogene-9789814585088/phttps://gandhi.vtexassets.com/arquivos/ids/2961122/7e5fef5b-0b28-4b72-aaaa-327963ed2ef3.jpg?v=6383846890563300009761084MXNSpringer Nature SingaporeInStock/Ebooks/<p>Cancer is initiated by activation of oncogenes or inactivation of tumor suppressor genes. Mutations in the K-ras proto-oncogene are responsible for 1030 of adenocarcinomas. Clinical Findings point to a wide variety of other cancers contributing to lung cancer incidence. Such a scenario makes identification of lung cancer difficult and thus identifying its mechanisms can contribute to the society. Identifying unique conserved patterns common to contributing proto-oncogenes may further be a boon to Pharmacogenomics and pharmacoinformatics. This calls for ab initio/de novo drug discovery that in turn will require a comprehensive in silico approach of Sequence, Domain, Phylogenetic and Structural analysis of the receptors, ligand screening and optimization and detailed Docking studies.</p><p>This brief involves extensive role of the RAS subfamily that includes a set of proteins, which cause an over expression of cancer-causing genes like M-ras and initiate tumour formation in lungs. SNP Studies and Structure based drug discovery will also be undertaken.</p>...2885841Bioinformatics of Non Small Cell Lung Cancer and the Ras Proto-Oncogene9761084https://www.gandhi.com.mx/bioinformatics-of-non-small-cell-lung-cancer-and-the-ras-proto-oncogene-9789814585088/phttps://gandhi.vtexassets.com/arquivos/ids/2961122/7e5fef5b-0b28-4b72-aaaa-327963ed2ef3.jpg?v=638384689056330000InStockMXN99999DIEbook20149789814585088_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9789814585088_<p>Cancer is initiated by activation of oncogenes or inactivation of tumor suppressor genes. Mutations in the K-ras proto-oncogene are responsible for 1030 of adenocarcinomas. Clinical Findings point to a wide variety of other cancers contributing to lung cancer incidence. Such a scenario makes identification of lung cancer difficult and thus identifying its mechanisms can contribute to the society. Identifying unique conserved patterns common to contributing proto-oncogenes may further be a boon to Pharmacogenomics and pharmacoinformatics. This calls for ab initio/de novo drug discovery that in turn will require a comprehensive in silico approach of Sequence, Domain, Phylogenetic and Structural analysis of the receptors, ligand screening and optimization and detailed Docking studies.</p><p>This brief involves extensive role of the RAS subfamily that includes a set of proteins, which cause an over expression of cancer-causing genes like M-ras and initiate tumour formation in lungs. SNP Studies and Structure based drug discovery will also be undertaken.</p>(*_*)9789814585088_<p>Cancer is initiated by activation of oncogenes or inactivation of tumor suppressor genes. Mutations in the K-ras proto-oncogene are responsible for 1030 of adenocarcinomas. Clinical Findings point to a wide variety of other cancers contributing to lung cancer incidence. Such a scenario makes identification of lung cancer difficult and thus identifying its mechanisms can contribute to the society. Identifying unique conserved patterns common to contributing proto-oncogenes may further be a boon to Pharmacogenomics and pharmacoinformatics. This calls for ab initio/de novo drug discovery that in turn will require a comprehensive in silico approach of Sequence, Domain, Phylogenetic and Structural analysis of the receptors, ligand screening and optimization and detailed Docking studies.</p><p>This brief involves extensive role of the RAS subfamily that includes a set of proteins, which cause an over expression of cancer-causing genes like M-ras and initiate tumour formation in lungs. SNP Studies and Structure based drug discovery will also be undertaken.</p>...9789814585088_Springer Singapore(*_*)9789814585088_Springer Nature Singaporelibro_electonico_e8a15338-a60c-30b7-bbc5-3f60877d70c8_9789814585088;9789814585088_9789814585088Naresh BabuInglésMéxicoSpringer Nature Singapore2014-09-08T00:00:00+00:00